A diagnostic test for the early detection of colon neoplasms: stool syndecan2 methylation test combined with blood tests for CEA and CA724.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300070079

Enrollment

Unknown

Registered

2023-03-31

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early detection of colon neoplasms

Interventions

Gold Standard:Pathological results

Index test:Stool syndecan2 methylation test

stool syndecan2 methylation test combined with blood tests for CEA and CA724

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 79 years old; (2) All are first-time patients; (3) No history of malignant tumors; (4) No history of radiotherapy or chemotherapy; (5) All patients were diagnosed with intestinal lesions through colonoscopy examination; (6) Willing to sign an informed consent form voluntarily; (7) Willing to provide a fecal sample for this study.

Exclusion criteria

Exclusion criteria: (1) Mental illness that prevents collaboration; (2) A history of severe chronic illnesses (including respiratory diseases, heart disease, kidney disease, liver disease, immune dysfunction, or the need for long-term immunosuppressive therapy); (3) Patients with tumors in other parts of the body; (4) Patients with multifocal lesions.

Design outcomes

Primary

Measure	Time frame
sensitivity;Positive predicative value, PPV;Positive predicative value, PPV;	—

Secondary

Measure	Time frame
specificity;	—

Countries

Chinese

Contacts

Public ContactJianping Cheng

Beijing Civil Aviation General Hospital

cjpczy2004@163.com+86 15811282039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026